Stimulatory effects of CpG ollgodeoxynucleotide on dendritic cell-based immunotherapy of colon cancer in CEA/HLA-A2 transgenic mice

Asim Sah, Malaya Bhattacharya-Chatterjee, Kenneth A. Foon, Esteban Celis, Sunil K. Chatterjee

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Immunostimulatory DNA containing unmethylated cytosine-guanine (CpG) motifs have been successfully used as adjuvants to enhance the immunity of vaccines designed to trigger antitumor T-cell responses. We examined the effect of a CpG oligodeoxynucleotide (CpG ODN) for its ability to potentiate the activity of tumor antigen-pulsed dendritic cells (DC) in a clinically relevant mouse model, which is transgenic for both careinoembryonic antigen (CEA) and HLA-A2 for the treatment of colon carcinoma in a therapeutic setting. The systemic administration of CpG ODN 1826 alone had modest effect on tumor growth when tumors were palpable and had no effect with larger tumor burden. However, coadministration of CpG ODN 1826 with the vaccine provided significant increase in tumor-free survival compared with mice immunized with DC-based vaccines alone. The DC/CpG combined vaccination strategy resulted in increased secretion of Thl cytokines and HLA-A2-restrieted CEA-speciflc CTL responses were also enhanced. Both tumor regression and extended tumor-free survival resulting from DC/CpG combination therapy required the participation of T cells. Tumor-free mice were resistant to tumor rechallenge and immunity conferred by the vaccine was transferable in athymic nude mice. These results provide evidence that vaccination with antigen-pulsed DC with CpG ODN as adjuvant can lead to effective tumor regression and long-term survival in a murine model of colon carcinoma.

Original languageEnglish (US)
Pages (from-to)877-888
Number of pages12
JournalInternational Journal of Cancer
Volume124
Issue number4
DOIs
StatePublished - Feb 15 2009

Fingerprint

HLA-A2 Antigen
Immunotherapy
Colonic Neoplasms
Dendritic Cells
Transgenic Mice
Oligodeoxyribonucleotides
Neoplasms
Vaccines
Nude Mice
Immunity
Colon
Vaccination
Carcinoma
T-Lymphocytes
Antigens
Cytosine
Guanine
Neoplasm Antigens
Tumor Burden
Therapeutics

Keywords

  • Antigen presenting cells
  • CEA
  • CEA-A2Kb double transgenic mice
  • CTL epitope
  • CpG ODN
  • antiidiotype antibody
  • dendritic cells

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Stimulatory effects of CpG ollgodeoxynucleotide on dendritic cell-based immunotherapy of colon cancer in CEA/HLA-A2 transgenic mice. / Sah, Asim; Bhattacharya-Chatterjee, Malaya; Foon, Kenneth A.; Celis, Esteban; Chatterjee, Sunil K.

In: International Journal of Cancer, Vol. 124, No. 4, 15.02.2009, p. 877-888.

Research output: Contribution to journalArticle

Sah, Asim ; Bhattacharya-Chatterjee, Malaya ; Foon, Kenneth A. ; Celis, Esteban ; Chatterjee, Sunil K. / Stimulatory effects of CpG ollgodeoxynucleotide on dendritic cell-based immunotherapy of colon cancer in CEA/HLA-A2 transgenic mice. In: International Journal of Cancer. 2009 ; Vol. 124, No. 4. pp. 877-888.
@article{b4c15c83e2d34432922a107af41662a9,
title = "Stimulatory effects of CpG ollgodeoxynucleotide on dendritic cell-based immunotherapy of colon cancer in CEA/HLA-A2 transgenic mice",
abstract = "Immunostimulatory DNA containing unmethylated cytosine-guanine (CpG) motifs have been successfully used as adjuvants to enhance the immunity of vaccines designed to trigger antitumor T-cell responses. We examined the effect of a CpG oligodeoxynucleotide (CpG ODN) for its ability to potentiate the activity of tumor antigen-pulsed dendritic cells (DC) in a clinically relevant mouse model, which is transgenic for both careinoembryonic antigen (CEA) and HLA-A2 for the treatment of colon carcinoma in a therapeutic setting. The systemic administration of CpG ODN 1826 alone had modest effect on tumor growth when tumors were palpable and had no effect with larger tumor burden. However, coadministration of CpG ODN 1826 with the vaccine provided significant increase in tumor-free survival compared with mice immunized with DC-based vaccines alone. The DC/CpG combined vaccination strategy resulted in increased secretion of Thl cytokines and HLA-A2-restrieted CEA-speciflc CTL responses were also enhanced. Both tumor regression and extended tumor-free survival resulting from DC/CpG combination therapy required the participation of T cells. Tumor-free mice were resistant to tumor rechallenge and immunity conferred by the vaccine was transferable in athymic nude mice. These results provide evidence that vaccination with antigen-pulsed DC with CpG ODN as adjuvant can lead to effective tumor regression and long-term survival in a murine model of colon carcinoma.",
keywords = "Antigen presenting cells, CEA, CEA-A2Kb double transgenic mice, CTL epitope, CpG ODN, antiidiotype antibody, dendritic cells",
author = "Asim Sah and Malaya Bhattacharya-Chatterjee and Foon, {Kenneth A.} and Esteban Celis and Chatterjee, {Sunil K.}",
year = "2009",
month = "2",
day = "15",
doi = "10.1002/ijc.24009",
language = "English (US)",
volume = "124",
pages = "877--888",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Stimulatory effects of CpG ollgodeoxynucleotide on dendritic cell-based immunotherapy of colon cancer in CEA/HLA-A2 transgenic mice

AU - Sah, Asim

AU - Bhattacharya-Chatterjee, Malaya

AU - Foon, Kenneth A.

AU - Celis, Esteban

AU - Chatterjee, Sunil K.

PY - 2009/2/15

Y1 - 2009/2/15

N2 - Immunostimulatory DNA containing unmethylated cytosine-guanine (CpG) motifs have been successfully used as adjuvants to enhance the immunity of vaccines designed to trigger antitumor T-cell responses. We examined the effect of a CpG oligodeoxynucleotide (CpG ODN) for its ability to potentiate the activity of tumor antigen-pulsed dendritic cells (DC) in a clinically relevant mouse model, which is transgenic for both careinoembryonic antigen (CEA) and HLA-A2 for the treatment of colon carcinoma in a therapeutic setting. The systemic administration of CpG ODN 1826 alone had modest effect on tumor growth when tumors were palpable and had no effect with larger tumor burden. However, coadministration of CpG ODN 1826 with the vaccine provided significant increase in tumor-free survival compared with mice immunized with DC-based vaccines alone. The DC/CpG combined vaccination strategy resulted in increased secretion of Thl cytokines and HLA-A2-restrieted CEA-speciflc CTL responses were also enhanced. Both tumor regression and extended tumor-free survival resulting from DC/CpG combination therapy required the participation of T cells. Tumor-free mice were resistant to tumor rechallenge and immunity conferred by the vaccine was transferable in athymic nude mice. These results provide evidence that vaccination with antigen-pulsed DC with CpG ODN as adjuvant can lead to effective tumor regression and long-term survival in a murine model of colon carcinoma.

AB - Immunostimulatory DNA containing unmethylated cytosine-guanine (CpG) motifs have been successfully used as adjuvants to enhance the immunity of vaccines designed to trigger antitumor T-cell responses. We examined the effect of a CpG oligodeoxynucleotide (CpG ODN) for its ability to potentiate the activity of tumor antigen-pulsed dendritic cells (DC) in a clinically relevant mouse model, which is transgenic for both careinoembryonic antigen (CEA) and HLA-A2 for the treatment of colon carcinoma in a therapeutic setting. The systemic administration of CpG ODN 1826 alone had modest effect on tumor growth when tumors were palpable and had no effect with larger tumor burden. However, coadministration of CpG ODN 1826 with the vaccine provided significant increase in tumor-free survival compared with mice immunized with DC-based vaccines alone. The DC/CpG combined vaccination strategy resulted in increased secretion of Thl cytokines and HLA-A2-restrieted CEA-speciflc CTL responses were also enhanced. Both tumor regression and extended tumor-free survival resulting from DC/CpG combination therapy required the participation of T cells. Tumor-free mice were resistant to tumor rechallenge and immunity conferred by the vaccine was transferable in athymic nude mice. These results provide evidence that vaccination with antigen-pulsed DC with CpG ODN as adjuvant can lead to effective tumor regression and long-term survival in a murine model of colon carcinoma.

KW - Antigen presenting cells

KW - CEA

KW - CEA-A2Kb double transgenic mice

KW - CTL epitope

KW - CpG ODN

KW - antiidiotype antibody

KW - dendritic cells

UR - http://www.scopus.com/inward/record.url?scp=58149477220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149477220&partnerID=8YFLogxK

U2 - 10.1002/ijc.24009

DO - 10.1002/ijc.24009

M3 - Article

C2 - 19035460

AN - SCOPUS:58149477220

VL - 124

SP - 877

EP - 888

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -